Allena begins Phase IIb trial of ALLN-177 to treat secondary hyperoxaluria
The randomized, crossover study Phase IIb trial is designed to evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.